Norbitec GmbH is a leading producer of biotechnologically produced erythropoietin (Epoetin zeta) for the treatment of anaemia. Founded in 2003 as a joint venture, the company is part of BIOCEUTICALS Arzneimittel AG, a subsidiary of STADA Arzneimittel AG.

Norbitec focuses on manufacturing high-quality erythropoietin, with key products including Silapo and Retacrit, approved for use in Europe since 2007. In 2023, the company received FDA approval to manufacture Epoetin zeta for the US market.

Key Products and Services

• Epoetin zeta (Silapo and Retacrit)
• Biotech production of erythropoietin
• European and US market approvals

With a robust focus on quality, Norbitec continues to lead in biotechnological drug production, ensuring the availability of life-saving treatments globally.